Proteasome Inhibition and Hematopoietic Stem Cell Transplantation in Multiple Myeloma

摘要: Multiple myeloma is a malignant plasma cell disorder in which the proliferation of ma‐ lignant cells leads to anemia, infections, bone fractures, hypercalcemia and renal dysfunction [1]. Affecting approximately 32,000 people each year worldwide, with median age onset 68 years, it second most common hematological malig‐ nancy after non-Hodgkin’s lymphoma (NHL). Two major advances have occurred treatment multiple last two decades: introduction high-dose che‐ motherapy autologous stem transplantation (ASCT), development active drugs novel mechanism action (proteasome inhibition immunomodulation). Both led significant improvements overall survival this disease.